VHL anticorps (N-Term)
-
- Antigène Voir toutes VHL Anticorps
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
-
Épitope
- N-Term
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp VHL est non-conjugé
-
Application
- Western Blotting (WB)
- Purification
- Purified
- Immunogène
- VHL antibody was raised in rabbit using the N terminal of VHL as the immunogen
- Top Product
- Discover our top product VHL Anticorps primaire
-
-
- Indications d'application
- Optimal conditions should be determined by the investigator.
- Commentaires
-
VHL Blocking Peptide, catalog no. 33R-2312, is also available for use as a blocking control in assays to test for specificity of this VHL antibody
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Concentration
- Lot specific
- Buffer
- Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
- Conseil sur la manipulation
- Avoid repeated freeze/thaw cycles.
- Stock
- 4 °C/-20 °C
- Stockage commentaire
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
- Antigène
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
- Autre désignation
- VHL (VHL Produits)
- Synonymes
- anticorps HRCA1, anticorps RCA1, anticorps VHL1, anticorps pVHL, anticorps BcDNA:RH61560, anticorps CG13221, anticorps DVhl, anticorps Dmel\\CG13221, anticorps Dvhl, anticorps VHL, anticorps d-VHL, anticorps d-vhl, anticorps dVHL, anticorps dmVHL, anticorps vhl, anticorps rca1, anticorps vhl1, anticorps hrca1, anticorps zgc:158722, anticorps Vhlh, anticorps von Hippel-Lindau tumor suppressor, anticorps von Hippel-Lindau, anticorps von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase, anticorps von Hippel-Lindau disease tumor suppressor, anticorps VHL, anticorps Vhl, anticorps vhl, anticorps CpipJ_CPIJ009992
- Sujet
- Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. Synonyms: Polyclonal VHL antibody, Anti-VHL antibody, von Hippel-Lindau tumor suppressor antibody, HRCA1 antibody, RCA1 antibody, VHL1 antibody.
- Pathways
- Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
-